Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Boehringer Ingelheim
Moodys
Express Scripts
Medtronic

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,730,926

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,730,926
Title:Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor
Abstract: Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.
Inventor(s): Lin; Powei (Hwaseong-si, KR), Cheong; Kwang Ho (Seoul, KR), Koh; Young Jun (Yongin-si, KR), Hwang; Jae-woong (Seoul, KR), Lee; Seung Hyun (Suwon-si, KR), Lee; Jung Wook (Yongin-si, KR)
Assignee: SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)
Application Number:14/600,986
Patent Claims:1. A method of treating a cancer comprising co-administering to a subject in need thereof a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject, wherein the bispecific anti-c-Met/anti-EGFR antibody comprises an EGFR binding region and an anti-c-Met antibody or antigen-binding fragment thereof, and wherein the anti c-Met antibody or the antigen-binding fragment thereof comprises a heavy chain variable region comprising a CDR-H1 comprising SEQ ID NO: 1, a CDR-H2 comprising SEQ ID NO: 2, and a CDR-H3 comprising SEQ ID NO: 3, and a light chain variable region comprising a CDR-L1 comprising SEQ ID NO: 10, a CDR-L2 comprising SEQ ID NO: 11, and a CDR-L3 comprising SEQ ID NO: 13, and wherein the cancer to be treated is colon cancer, lung cancer, colon cancer comprising a K-Ras mutation, or lung cancer comprising an EGFR T790M mutation.

2. The method of claim 1, wherein the bispecific anti-c-Met/anti-EGFR antibody and the Src inhibitor are co-administered by administering a composition comprising the bispecific anti-c-Met/anti-EGFR antibody and the c-Src inhibitor, or administering a first composition comprising the bispecific anti-c-Met/anti-EGFR antibody and a second composition comprising the c-Src inhibitor, wherein the first composition and second composition are administered simultaneously or sequentially in any order.

3. The method of claim 1, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising SEQ ID NO: 17; and a light chain variable region comprising SEQ ID NO: 129 or SEQ ID NO: 18.

4. The method of claim 1, wherein the anti-c-Met antibody comprises: a heavy chain comprising SEQ ID NO: 62, the 18th to 462nd positions of SEQ ID NO: 62, SEQ ID NO: 64, the 18th to 461st positions of SEQ ID NO: 64, SEQ ID NO: 66, or the 18th to 460th positions of SEQ ID NO: 66; and a light chain comprising SEQ ID NO: 68, the 21st to 240th positions of SEQ ID NO: 68, SEQ ID NO: 70, the 21st to 240th positions of SEQ ID NO: 70, or SEQ ID NO: 108.

5. The method of claim 1, wherein the EGFR binding region comprises an anti-EGFR antibody, antigen-binding fragment thereof, or an anti-EGFR DARPin.

6. The method of claim 5, wherein the anti-EGFR antibody or antigen-binding fragment thereof is selected from the group consisting of: (1) cetuximab or antigen binding fragment thereof; (2) panitumumab or antigen binding fragment thereof; (3) an anti-EGFR antibody comprising a heavy chain variable region comprising SEQ ID NO: 109, and a light chain variable region comprising SEQ ID NO: 111; (4) an anti-EGFR antibody comprising a heavy chain variable region comprising SEQ ID NO: 113, and a light chain variable region comprising SEQ ID NO: 114; and (5) an anti-EGFR antibody comprising a CDR-H1 comprising SEQ ID NO: 115, a CDR-H2 comprising SEQ ID NO: 116, and a CDR-H3 comprising SEQ ID NO: 117, a CDR-L1 comprising SEQ ID NO: 118, a CDR-L2 comprising SEQ ID NO: 119, and a CDR-L3 comprising SEQ ID NO: 120.

7. The method of claim 6, wherein the anti-EGFR antibody or antigen-binding fragment thereof is an anti-EGFR antibody, an anti-EGFR scFv, or an anti-EGFR scFv-Fc comprising a heavy chain variable region comprising SEQ ID NO: 109, SEQ ID NO: 113, SEQ ID NO: 121, or SEQ ID NO: 122; and a light chain variable region comprising SEQ ID NO: 111, SEQ ID NO: 114, SEQ ID NO: 123, or SEQ ID NO: 124.

8. The method of claim 5, wherein the EGFR binding region comprises an anti-EGFR DARPin, and the anti-EGFR DARPin comprises 1 to 10 units, wherein each unit is independently selected from the group consisting of SEQ ID NOs: 125 to 127.

9. The method of claim 1, wherein the c-Src inhibitor is at least one selected from the group consisting of dasatinib, saracatinib, bosutinib, 1-Naphthyl PP1 (CAS 221243-82-9), A 419259 trihydrochloride (CAS 364042-47-7), AG 538 (CAS 133550-18-2), AGL 2263 ((E)-2-(3,4-dihydroxybenzoyl)-3-(2-oxo-3H-1,3-benzoxazol-5-yl)prop-2-enen- itrile), Bcr-abl Inhibitor II (CAS 607702-99-8), bosutinib (CAS 380843-75-4), altenusin (CAS 31186-12-6), herbimycin A(CAS 70563-58-5), PD 166285 (CAS 212391-63-4), PKC-412 (CAS 120685-11-2), PDGFR Tyrosine Kinase Inhibitor IV (CAS 627518-40-5), Calphostin C (CAS 121263-19-2), PP 1 (CAS 172889-26-8), PP 2 (CAS 172889-27-9), Src Kinase Inhibitor I (CAS 179248-59-0), EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor (CAS 1135256-66-4), staurosporine (CAS 62996-74-1), lavendustin A (CAS 125697-92-9), Indirubin-3'-(2,3-dihydroxypropyl)oximether, luteolin (CAS 491-70-3), SU6656 (CAS 330161-87-0), TX-1918 (CAS 503473-32-3), geldanamycin (CAS 0562-34-6), MNS (CAS 1485-00-3), TX-1123 (CAS 157397-06-3), GW5074 (CAS 220904-83-6), Erlotinib HCl (CAS 183319-69-9), NVP-BHG712 (CAS 940310-85-0), GW2580 (CAS 870483-87-7), AEE788 (CAS 497839-62-0), TAK-901 (CAS 934541-31-8), Midostaurin (CAS 120685-11-2), and PD173074 (CAS 219580-11-7), or any combination thereof.

10. A pharmaceutical composition comprising a bispecific anti-c-Met/anti-EGFR antibody of claim 1 and a carrier.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2014-0006903Jan 20, 2014

Details for Patent 9,730,926

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) 2034-01-20 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) 2034-01-20 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) 2034-01-20 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) 2034-01-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Boehringer Ingelheim
Merck
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.